{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T08:07:49Z","timestamp":1772957269254,"version":"3.50.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Medizinischen Hochschule Hannover","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015649","name":"L\u00e6gemiddelstyrelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcpo.2025.100696","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:12:54Z","timestamp":1766189574000},"page":"100696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Innovative oncology trial designs: Time to act \u2013 A review with recommendations of the Cancer Drug Development Forum"],"prefix":"10.1016","volume":"47","author":[{"given":"Rosa","family":"Giuliani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafsika","family":"Kronidou-Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A\u00e1ron","family":"Sosa Mejia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lada","family":"Leyens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodor","family":"Framke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergus","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Collette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Bogaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9314","authenticated-orcid":false,"given":"Stefan N.","family":"Symeonides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2025.100696_bib1","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.clinthera.2016.07.018","article-title":"New methods and designs of clinical trials","volume":"38","author":"Pontes","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jcpo.2025.100696_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15441\/ceem.23.036","article-title":"Overview of clinical study designs","volume":"11","author":"Kim","year":"2024","journal-title":"Clin. Exp. Emerg. Med"},{"key":"10.1016\/j.jcpo.2025.100696_bib3","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1002\/cncr.33205","article-title":"Clinical trial design: past, present, and future in the context of big data and precision medicine","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jcpo.2025.100696_bib4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cpt.2832","article-title":"A review of the evolving landscape of inclusive research and improved clinical trial access","volume":"113","author":"Mohan","year":"2023","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jcpo.2025.100696_bib5","author":"IQVIA","year":"2022","journal-title":"Inst. Rep. Glob. Oncol. Trends 2022 Outlook 2026"},{"key":"10.1016\/j.jcpo.2025.100696_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2025.100696_bib7","article-title":"Master protocols: new directions in drug discovery","volume":"18","author":"Bogin","year":"2020","journal-title":"Conte Clin. Trials Commun."},{"key":"10.1016\/j.jcpo.2025.100696_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102384","article-title":"Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL","volume":"67","author":"Koenig","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcpo.2025.100696_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06312-x","article-title":"Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer","volume":"23","author":"Snowdon","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jcpo.2025.100696_bib10","unstructured":"Food and Drug Administration, Master Protocols for Drug and Biological Product Development Guidance for Industry Draft Guidance, 2023. \u3008https:\/\/www.fda.gov\/media\/174976\/download\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib11","unstructured":"European Medicines Agency, Concept paper on platform trials, 2022. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-platform-trials_en.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jcpo.2025.100696_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-6-79","article-title":"Benefits, challenges and obstacles of adaptive clinical trial designs","volume":"6","author":"Chow","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jcpo.2025.100696_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-024-02272-9","article-title":"Adaptive designs in clinical trials: a systematic review-part I","volume":"24","author":"Ben-Eltriki","year":"2024","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.jcpo.2025.100696_bib15","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), European Medicines Agency, ICH E20 Guideline on adaptive designs for clinical trials Step 2b, 2025. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e20-guideline-adaptive-designs-clinical-trials-step-2b_en.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2025.100696_bib17","article-title":"The PRECIS-2 tool: designing trials that are fit for purpose","volume":"350","author":"Loudon","year":"2015","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.jcpo.2025.100696_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_100040","article-title":"Pragmaticism in cancer clinical trials","volume":"44","author":"Sankar","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.jcpo.2025.100696_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2522\/ptj.2016.96.2.137","article-title":"Pragmatic clinical trials: implementation opportunity, or just another fad?","volume":"96","author":"Delitto","year":"2016","journal-title":"Phys. Ther."},{"key":"10.1016\/j.jcpo.2025.100696_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111566","article-title":"Modern trials are most useful when they are pragmatic and explanatory \u2013 there is no continuum","volume":"176","author":"Janiaud","year":"2024","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jcpo.2025.100696_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/03009734.2018.1515280","article-title":"Pragmatic clinical trials in the context of regulation of medicines","volume":"124","author":"Gedeborg","year":"2019","journal-title":"Ups. J. Med Sci."},{"key":"10.1016\/j.jcpo.2025.100696_bib22","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1158\/1078-0432.CCR-19-0820","article-title":"Design and evaluation of an external control arm using prior clinical trials and real-world data","volume":"25","author":"Ventz","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcpo.2025.100696_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01799-z","article-title":"External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning","volume":"22","author":"Loiseau","year":"2022","journal-title":"BMC Med Res Method."},{"key":"10.1016\/j.jcpo.2025.100696_bib24","unstructured":"Food and Drug Administration, Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products Guidance for Industry Draft Guidance, 2023 \u3008https:\/\/www.fda.gov\/media\/164960\/download\u3009(accessed November 27, 2025).."},{"key":"10.1016\/j.jcpo.2025.100696_bib25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/pst.2120","article-title":"The use of external controls: to what extent can it currently be recommended?","volume":"20","author":"Burger","year":"2021","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.jcpo.2025.100696_bib26","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.annonc.2021.12.015","article-title":"External control arms in oncology: current use and future directions","volume":"33","author":"Mishra-Kalyani","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jcpo.2025.100696_bib27","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.jcpo.2025.100696_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jcpo.2025.100696_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcpo.2025.100696_bib30","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/eurheartj\/ehv164","article-title":"The perils of surrogate endpoints","volume":"36","author":"Weintraub","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jcpo.2025.100696_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the us food and drug administration\u2019s approval of oncology drugs","author":"Kim","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jcpo.2025.100696_bib32","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.3390\/curroncol30090603","article-title":"Beyond participation: evaluating the role of patients in designing oncology clinical trials","volume":"30","author":"Farah","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jcpo.2025.100696_bib33","doi-asserted-by":"crossref","first-page":"k4738","DOI":"10.1136\/bmj.k4738","article-title":"Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis","volume":"363","author":"Crocker","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2025.100696_bib34","doi-asserted-by":"crossref","unstructured":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health, Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance, Health Qual Life Outcomes 4 (2006) 79. https:\/\/doi.org\/10.1186\/1477-7525-4-79.","DOI":"10.1186\/1477-7525-4-79"},{"key":"10.1016\/j.jcpo.2025.100696_bib35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","author":"Kluetz","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book 35"},{"key":"10.1016\/j.jcpo.2025.100696_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","article-title":"The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making","volume":"24","author":"Bellino","year":"2024","journal-title":"Drugs R. D."},{"key":"10.1016\/j.jcpo.2025.100696_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12916-023-02969-6","article-title":"Why estimands are needed to define treatment effects in clinical trials","volume":"21","author":"Keene","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.jcpo.2025.100696_bib38","first-page":"883","article-title":"Estimands - A Basic Element for Clinical Trials","volume":"118","author":"Pohl","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jcpo.2025.100696_bib39","unstructured":"Committee for Medicinal Products for Human Use, ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials, 2020. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf\u3009 (accessed November 28, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib40","article-title":"The estimands framework: a primer on the ICH E9(R1) addendum","volume":"384","author":"Kahan","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2025.100696_bib41","unstructured":"European Medicines Agency, Mandate, objectives and rules of procedure for EMA working parties under the domains, 2025. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/other\/mandate-objectives-rules-procedure-working-parties-under-quality-non-clinical-methodology-clinical-veterinary-domains_en.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068177","article-title":"Early phase clinical trials extension to guidelines for the content of statistical analysis plans","volume":"376","author":"Homer","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2025.100696_bib43","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1001\/jama.2023.19793","article-title":"Reporting of factorial randomized trials: extension of the CONSORT 2010 statement","volume":"330","author":"Kahan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2025.100696_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46121","article-title":"Consensus statement for protocols of factorial randomized trials: extension of the SPIRIT 2013 statement","volume":"6","author":"Kahan","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2025.100696_bib45","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Harmonised Guideline: Guideline for Good Clinical Practice E6(R3), 2025. \u3008https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib46","unstructured":"Food and Drug Administration, Project Optimus: reforming the dose optimization and dose selection paradigm in oncology, (2024). \u3008https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1144056","article-title":"Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective","volume":"13","author":"Murphy","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.jcpo.2025.100696_bib48","unstructured":"Food and Drug Administration, Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry, 2022. \u3008https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugsand\/or\u3009."},{"key":"10.1016\/j.jcpo.2025.100696_bib49","unstructured":"European Commission, European Medicines Agency, Heads of Medicine Agencies, Complex clinical trials - Questions and answers, 2022. \u3008https:\/\/health.ec.europa.eu\/system\/files\/2022-06\/medicinal_qa_complex_clinical-trials_en.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib50","unstructured":"Food and Drug Administration, Interacting with the Food and Drug Administration on Complex Innovative Clinical Trial Designs for Drugs and Biological Products, Guidance for Industry, 2020. \u3008https:\/\/www.fda.gov\/media\/130897\/download\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib51","unstructured":"Committee for Medicinal Products for Human Use, European Medicines Agency, Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design, London, 2007. \u3008https:\/\/virtualdev.emwa.org\/Documents\/Freelancer\/adaptivestudydesign\/EMA%20adaptive%20design_Oct%202007.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cpt.2914","article-title":"Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions","volume":"114","author":"Sola-Morales","year":"2023","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jcpo.2025.100696_bib53","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s43441-024-00693-8","article-title":"A framework for the use and likelihood of regulatory acceptance of single-arm trials","volume":"58","author":"Subramaniam","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.jcpo.2025.100696_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2023.03.013","article-title":"Defining the role of real-world data in cancer clinical research: the position of the European Organisation for Research and Treatment of Cancer","volume":"186","author":"Saesen","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jcpo.2025.100696_bib55","unstructured":"ER4Health Partnership, Call for proposals 2025 Fostering Pragmatic Comparative-Effectiveness Trials in Non-communicable Diseases (EffecTrial), 2025. \u3008https:\/\/era4health.eu\/calls\/docs\/EffecTrial_Pre-announcement.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib56","unstructured":"Clinical Research Expert Group (CREG) Working Group, Integrated Evidence Generation and Use (IEGU) Working Group, An EFPIA position paper on randomised pragmatic trials to generate high-quality real-world evidence for regulatory decisions, 2023. \u3008https:\/\/www.efpia.eu\/media\/guokpw0b\/an-efpia-position-paper-on-randomised-pragmatic-trials-to-generate-high-quality-real-world-evidence-for-regulatory-decisions.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib57","unstructured":"Food and Drug Administration, Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure, (2025). \u3008https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib58","unstructured":"Heads of HTA Agencies Group, European Medicines Agency, Joint HTAb-regulatory perspectives on understanding evidence challenges, managing uncertainties and exploring potential solutions, 2025. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/other\/joint-htab-regulatory-perspectives-understanding-evidence-challenges-managing-uncertainties-exploring-potential-solutions_en.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib59","unstructured":"European Medicines Agency, Conditional marketing authorisation, (n.d.). \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib60","unstructured":"European Medicines Agency, Conditional marketing authorisation: Report on ten years of experience at the European Medicines Agency, 2017. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/report\/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib61","unstructured":"Food and Drug Administration, Accelerated Approval Program, (2025). \u3008https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/accelerated-approval-program\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cpt.1169","article-title":"Postauthorization changes to specific obligations of conditionally authorized medicines in the european union: a retrospective cohort study","volume":"105","author":"Bloem","year":"2019","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jcpo.2025.100696_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-084483","article-title":"Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study","volume":"14","author":"van Hattem","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcpo.2025.100696_bib64","unstructured":"European Medicines Agency, Clinical Trials Regulation, (2023). \u3008https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-regulation\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib65","article-title":"European survey on national harmonization in clinical research","volume":"5","author":"Magnin","year":"2021","journal-title":"Learn Health Syst."},{"key":"10.1016\/j.jcpo.2025.100696_bib66","unstructured":"European Commission, European Medicines Agency, Heads of Medicine Agencies, Monitoring the European clinical trials environment, 2024. \u3008https:\/\/accelerating-clinical-trials.europa.eu\/document\/download\/a9886721-f614-4c17-a3dc-53137a63d7bc_en?filename=ACT%20EU%20KPI%20Report%20Jan-Mar%202025.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13063-023-07869-x","article-title":"Experiences and challenges with the new European Clinical Trials Regulation","volume":"25","author":"Patrick-Brown","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.jcpo.2025.100696_bib68","unstructured":"European Medicines Agency, New clinical trial map launched in the EU, (2025). \u3008https:\/\/www.ema.europa.eu\/en\/news\/new-clinical-trial-map-launched-eu\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib69","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2340\/1651-226X.2024.34791","article-title":"PRIME-ROSE Consortium and the PCM4EU Consortium, PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe","volume":"63","author":"Task\u00e9n","year":"2024","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jcpo.2025.100696_bib70","unstructured":"European Commission, Personalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer, (2025). \u3008https:\/\/cordis.europa.eu\/project\/id\/101136812\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib71","unstructured":"European Federation of Pharmaceutical Industries and Associations, Improving EU Clinical Trials: Proposals to Overcome Current Challenges and Strengthen the Ecosystem, 2025. \u3008https:\/\/www.efpia.eu\/media\/pl0nag0s\/efpias-list-of-proposals-clinical-trials-15-apr-2025.pdf\u3009 (accessed November 27, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib72","unstructured":"European Medicines Agency, EMA welcomes political agreement on new EU pharmaceutical legislation, (2025). (https:\/\/www.ema.europa.eu\/en\/news\/ema-welcomes-political-agreement-new-eu-pharmaceutical-legislation). (accessed December 23, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib73","unstructured":"European Medicines Agency, Information about the clinical study data proof-of-concept pilot for industry, (2024). (https:\/\/www.ema.europa.eu\/en\/documents\/other\/information-about-clinical-study-data-proof-concept-pilot-industry_en.pdf). (accessed December 23, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib74","unstructured":"European Commission, Proposal for a regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394\/2007 and Regulation (EU) No 536\/2014 and repealing Regulation (EC) No 726\/2004, Regulation (EC) No 141\/2000 and Regulation (EC) No 1901\/2006, (2023) (https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:52023PC0193). (accessed December 23, 2025)."},{"key":"10.1016\/j.jcpo.2025.100696_bib75","unstructured":"European Medicines Agency, New targets for clinical trials in Europe, (2025). (https:\/\/www.ema.europa.eu\/en\/news\/new-targets-clinical-trials-europe). (accessed December 23, 2025)."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325001407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325001407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:52:07Z","timestamp":1772923927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325001407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":75,"alternative-id":["S2213538325001407"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100696","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative oncology trial designs: Time to act \u2013 A review with recommendations of the Cancer Drug Development Forum","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100696"}}